Novartis India has posted a net profit of Rs 373.10 million for the quarter ended June 30,2005 against Rs 211.40 million for the quarter ended June 30, 2004. Total Income is Rs 1687.70 million as compared to total income of Rs 1384.80 million in Q1-05.
Other income includes profit of Rs 25.6 million on sale of the Rifampicin bulk drug business with its facility situated at Mahad, Maharashtra effective April 01, 2005 on a going concern basis to Sandoz Pvt Ltd for a consideration of Rs 350.50 million, according to a company release.